Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

AUTOR(ES)

Ataei-Nakhaei, Saeideh; Aryana, Kamran; Mostafavi, Sayyed Mostafa; Kosari, Hadis Mohammadzadeh; Esmatinia, Mohammad; Aghaee, Atena

FONTE

Archives of Endocrinology and Metabolism

DATA DE PUBLICAÇÃO

2022

RESUMO

SUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.

Documentos Relacionados

• Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
• Radioiodine for thyroid cancer: sometimes, less is best
• Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
• Trichomonal vaginitis refractory to treatment: case report.
• Radionuclide therapy for thyroid disease.